Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7137518 | 0.90 | CNR1 (0.49) | LMNATAAR1HPGDALDH1A1KMT2A | |
| SCHEMBL7139406 | 0.90 | LMNA (0.51) | LMNAHPGDALDH1A1KMT2APKM | |
| SCHEMBL7131854 | 0.89 | KMT2A (0.44) | LMNAHPGDALDH1A1KMT2APKM | |
| SCHEMBL7136761 | 0.86 | EPHX1 (0.50) | LMNAHPGDALDH1A1KMT2APKM | |
| SCHEMBL7137508 | 0.85 | LMNA (0.44) | LMNAHPGDALDH1A1KMT2APKM | |
| SCHEMBL7133782 | 0.85 | PTPN1 (0.49) | LMNATAAR1HPGDALDH1A1KMT2A | |
| SCHEMBL7136924 | 0.85 | HPGD (0.46) | LMNATAAR1HPGDALDH1A1KMT2A | |
| SCHEMBL7135503 | 0.84 | ALDH1A1 (0.46) | LMNAHPGDALDH1A1KMT2ACNR1 | |
| SCHEMBL7130614 | 0.84 | LMNA (0.45) | LMNAHTTSMN1; SMN2 | |
| SCHEMBL7136859 | 0.83 | EPHX2 (0.56) | LMNAHPGDALDH1A1KMT2ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | LMNA 2624/4885TAAR1 4810/4885HPGD 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.